NCT02178566View on ClinicalTrials.gov

Pulmonary Rehab in Chronic Obstructive Pulmonary Disease (COPD): Response to Tyvaso

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

January 31, 2019

Study Completion Date

January 31, 2019

Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
DRUG

Inhaled Treprostinil

A dose of inhaled treprostinil or placebo will be administered to all study participants prior to each of their Pulmonary Rehab sessions. Three puffs of inhaled treprostinil dose will be administered each time to all patients .

Trial Locations (1)

22042

Inova Fairfax Medical Campus, Falls Church

Sponsors
All Listed Sponsors
lead

Inova Health Care Services

OTHER